Next Phase Newsletter

This venture capital fund was established by a group of high-net-worth individuals in China and maintains operations in the US and China. The firm is actively seeking global investment opportunities, with a primary focus on China and the United States. Opportunities based in Canada, Germany, and Switzerland may also be considered. 

The firm invests from seed and early stages through growth, with flexibility on check size for early-stage deals. For growth-stage companies, the firm typically invests $1-5M in equity in businesses with valuations up to $18-20M. Investments at earlier stages may take the form of equity or convertible notes. Thanks to an evergreen fund structure, the firm is able to take a long-term investment approach. It usually syndicates investments and seeks to partner with local co-investors, particularly for overseas deals. 

 
The firm targets high-growth sectors, including medical devices, diagnostics (e.g., portable imaging, high-intensity ultrasound, point-of-care, molecular diagnostics), digital health (particularly connected devices, telemedicine, and patient-physician platforms relevant to the Chinese market), and consumer products, especially OTC products, nutritional and dietary supplements with proven efficacy and existing market presence. 
 

The firm is indication-agnostic and prioritizes serial entrepreneurs and complete, well-rounded founding teams. It relies on local co-investors to play supervisory roles in international ventures. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An investment firm headquartered in China invests in both fund-of-funds and direct equity opportunities. Life sciences and healthcare represent one of its primary focus areas, though the firm maintains a multi-sector approach. Its investment sweet spot begins at the pre-A stage and extends through to pre-IPO. While the firm primarily targets opportunities within China, it is open to global companies, particularly those seeking a soft landing in China or with a strong China angle. The firm is flexible on deal structure and is open to both leading investments and co-investments. 

Within the healthcare and life sciences sector, the firm is especially interested in biotech therapeutics and medtech. On the therapeutics side, it is open to a range of modalities (excluding mRNA) and indications, with particular interest in areas such as central nervous system (CNS) disorders and oncology. On the medical device side, the firm prioritizes innovative technologies, including invasive solutions, imaging platforms, and brain-computer interfaces. It does not invest in non-innovative categories such as consumables. 

The firm does not maintain strict requirements regarding the background of founding teams, though it has a strong preference for companies that are interested in expanding into Shanghai or the broader Chinese market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An early-stage venture capital firm focuses on deeptech innovation, with strategic emphasis on the Cleantech and Biotech sectors. The firm acknowledges the critical role that advanced materials play in promoting both planetary and human health. 

The firm typically invests from Pre-Seed through Series A, with average initial allocations around USD $500k and reserves for follow-on participation. Geographically, the firm targets North America and Asia, and is also open to public-ready companies or those preparing to go public. 

Within biotech, the firm seeks novel therapeutics and global health-enhancing medical breakthroughs. While broadly sector-agnostic, the firm prioritizes companies with a technology backbone. Preferred areas include: platform technologies, enabling tools for drug discovery & development, and synthetic biology 

The firm is indication-agnostic, though generally less interested in infectious diseases. 

There are no strict team or company prerequisites, though the firm prefers to have an investor presence on the board. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital corporation is based in Canada with the government serving as a limited partner participates in Angel through Series A rounds, typically allocating CAD $100K to $200K for Angel rounds and CAD $500K to $1M for Pre-A and Series A rounds. It is open to co-investments and occasionally acts as a limited partner in other investment funds. The firm seeks innovative projects that align with the interests of its affiliated operating company, which specializes in immunology-based diagnostics. 

In addition to direct investments, the firm in-licenses intellectual property from universities and engages in joint ventures with other partners. With its own internal management and engineering team, the firm plays an active role in helping startups enter the market and commercialize their products. The firm is open to working with companies globally. 

Its core areas of interest include AI-driven digital health, medical devices, and diagnostics – particularly those involving antigen and antibody pairs. The firm favors companies that are nearing commercialization and can be integrated into its existing AI platform. A board seat is typically preferred in investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital investor based in Asia with a presence in the US makes early- to expansion-stage investments across multiple sectors, ranging from smart cities and fintech to healthcare. Investment size is highly variable depending on the company’s stage. The firm invests alongside other venture capital firms in companies located in North America and Europe that have a market expansion strategy into Asia. 

The firm takes an opportunistic approach to digital healthcare companies, particularly those leveraging AI and bioinformatics to accelerate the drug discovery process. 

The firm seeks entrepreneurs who are passionate, driven, and enthusiastic, with sustainable business models and globally scalable ideas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An investment bank headquartered in the US  does not act as a traditional investment bank, as the firm participates in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public markets. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes a sister company to further analyze company technologies and IPs. The firm can fund from $5-12M USD from Seed to Series A rounds with preference in US-based companies, though the firm is open to global companies. 
 
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS. 
 

The firm works closely with companies and founders and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm, founded in 2019, is a global venture capital investor. The firm specializes in early-stage medical device companies and actively leverages expertise and industry resources to support portfolio companies. The firm prefers taking a leading role in investment rounds and may seek board seats in such cases. 

The firm focuses on medical devices and is open to all subsectors and indications. The firm seeks innovative technologies, primarily investing in Class III devices, and occasionally considers Class II devices if they demonstrate significant innovation. The firm is open to working with companies at all stages, including those in the early idea phase. 

The firm prefers founding teams with strong scientific expertise and comprehensive knowledge of their respective fields. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology